Skip to main content
. 2014 Mar 4;7(2):188–195. doi: 10.1016/j.tranon.2014.02.003

Figure 2.

Figure 2

Analysis of Ang2 levels in patient plasma. (A) Patients with metastatic RCC have higher circulating plasma Ang2 levels than patients with (low burden) stage 1 RCC or healthy controls (***P < 0.001). (B) Plasma analysis in patients at baseline prior to treatment with sunitinib, ~ day 28 after starting sunitinib, and at the time of progression on sunitinib shows that Ang2 levels decrease with sunitinib treatment and increase at the time of disease progression (**P < 0.01 for both comparisons). Data are expressed as means ± SD.